A pharmaceutical start-up that promised a year ago to undersell the drug industry took aim at a pharma blockbuster this week. The company, EQRx, is led by biotech veteran Alexis Borisy, whose Foundation Medicine was bought by Roche in 2018 for $5.3 billion. EQRx has raised $750 million in venture capital.
The company aims to develop drugs that compete with brand-name, patented medications—at a fraction of the price. It has been relatively quiet so far, signing licensing deals for a handful of cancer medications. But on Wednesday…